Digg Delicious Twitter RSS

Tratamientos

C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells

Miércoles 08 de Febrero de 2012 13:56

C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells

Giselle Pentón-Rol, Gregorio Martínez-Sánchez, Majel Cervantes-Llanos, Nielsen Lagumersindez-Denis, Emilio Felino Acosta-Medina b, Viviana Falcón-Cama,
Ruby Alonso-Ramírez, Carmen Valenzuela-Silva, Efraín Rodríguez-Jiménez, Alexey Llópiz-Arzuaga, Javier Marín-Prida, Pedro Antonio López-Saura, Gerardo Emilio Guillén-Nieto, Eduardo Pentón-Arias

For decades Experimental Autoimmune Encephalitis (EAE) has remained as an unsurpassed multiple sclerosis (MS) animal model. C-Phycocyanin (C-Pc) has been reported to exhibit pharmacological properties that may be expected to symptomatically improve EAE and MS. However, in this paper we reveal a basic underlying mechanism that may provide a new approach to the rationale of the overall beneficial effect of this natural antioxidant. We demonstrate that C-Pc is able to trigger mechanisms preventing or downgrading EAE expression and induces a regulatory T cell (Treg) response, in peripheral blood mononuclear cells (PBMC) from MS patients. These results agree with reports suggesting that Treg limit acute MS attacks and that C-Pc may act as a neuroprotector and thereby reverts the organic and functional damage in neurodegenerative disorders of the central nervous system (CNS). Moreover, evidence is provided on the antioxidant activity of C-Pc within the CNS, intended to improve the myelin and axonal damage of EAE induced Lewis rats. Our results indicate that specific Treg activation may represent a central and essential mechanism in supporting the therapeutic potential of C-Pc for MS and may lead to new and more effective therapies; this property would then complement and enhance other proven active principles such as interferons (IFN), giving rise to combined therapies.

icon C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells

Escribir un comentario

Emerging oral therapies for Multiple Sclerosis.

Miércoles 08 de Febrero de 2012 13:56

Multiple sclerosis (MS) is a demyelinating autoimmune disease of the central nervous system (CNS). A continuous deposition of sclerotic plaques leads to progressive physical disability. Etiological, exacerbating or remitting agents and curative treatments have not been firmly established.

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is a representative European organization that facilitates communication and creates synergies among clinicians and scientists to promote and enhance research and improve clinical outcomes in multiple sclerosis. ECTRIMS hosts the world’s largest annual international conference devoted to basic and clinical research in multiple sclerosis. This year the 25th ECTRIMS Congress was held in Düsseldorf, Germany, 9–12 September 2009.

ECTRIMS congresses have over the years evolved into the largest and most important annual international meeting devoted to multiple sclerosis. International experts in MS research, both scientists and clinicians, shared and discussed recent advances in this fast moving field. Clearly, the ultimate goal of all these efforts is to combat and eventually cure this disabling disease which affects some two million individuals throughout the world. A better understanding of the immunopathological processes underlying MS has in recent years led to the design of numerous novel therapeutical approaches. At the ECTRIMS special attention was paid to oral therapies, a topic which we would like to comment for you in this report.

Multiple sclerosis (MS) represents the prototypic

inflammatory autoimmune disorder of the CNS and the most common cause of neurological disability in young adults, exhibiting considerable clinical, radiological and pathological heterogeneity.

icon Emerging oral therapies for Multiple Sclerosis. Report of the 25th Congress of the European Committe

Escribir un comentario